ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Dapagliflozin Shields Kidneys from Acute Injury. 11/07/25"
Episode Synopsis
Welcome to Cardiology Today – Recorded November 07, 2025. This episode summarizes 5 key cardiology studies on topics like neutrophils and incident stroke. Key takeaway: Dapagliflozin Shields Kidneys from Acute Injury..
Article Links:
Article 1: A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy. (The New England journal of medicine)
Article 2: Advancing Assessment Methods for Human Cardiac Grafts During Normothermic Machine Perfusion. (Transplantation)
Article 3: Adenosine-mediated Neutrophil Regulation by Dapagliflozin Attenuates Renal Ischemia/Reperfusion Injury: Real-time Imaging and Metabolic Insights. (Transplantation)
Article 4: Cardiac resynchronisation therapy among adults with a systemic right ventricle: a multicentre experience. (Heart (British Cardiac Society))
Article 5: Higher Burden of Cerebral Small Vessel Disease Is Associated With Risk of Incident Stroke in Community-Dwelling Individuals. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/dapagliflozin-shields-kidneys-from-acute-injury-11-07-25/
Featured Articles
Article 1: A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41196369
Summary: This Phase 3 trial investigated atacicept as a potential treatment for IgA nephropathy, a severe kidney disorder often leading to kidney failure or death in 50 percent of patients. Atacicept is a T.A.C.I.-Fc fusion protein designed to inhibit B-cell activating factor and a proliferation-inducing ligand, targeting the B-cell origin of the disease. This research establishes a crucial step in evaluating a specific immunomodulatory therapeutic approach for a condition affecting many patients with progressive kidney failure. The study explores a targeted strategy to improve outcomes in this prevalent primary glomerulopathy.
Article 2: Advancing Assessment Methods for Human Cardiac Grafts During Normothermic Machine Perfusion.
Journal: Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41195985
Summary: This study focused on advancing assessment methods for human cardiac grafts during normothermic machine perfusion, addressing the critical challenge of donor heart scarcity in transplantation. Heart transplantation is the gold standard for end-stage heart failure, but only one-third of available donor hearts are currently utilized due to stringent selection criteria. By improving graft preservation and assessment through normothermic machine perfusion, this research aims to significantly increase the number of viable donor hearts. This advancement is crucial for expanding access to life-saving heart transplantation for millions affected by severe heart failure.
Article 3: Adenosine-mediated Neutrophil Regulation by Dapagliflozin Attenuates Renal Ischemia/Reperfusion Injury: Real-time Imaging and Metabolic Insights.
Journal: Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41195983
Summary: This study investigated the renoprotective mechanisms of dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, in attenuating acute kidney injury resulting from ischemia/reperfusion injury in nondiabetic mice. Researchers found that dapagliflozin achieved its protective effects through adenosine-mediated neutrophil regulation, a pathway further elucidated by concurrent treatment with an adenosine A2A receptor antagonist. This research provides crucial metabolic insights and demonstrates that dapagliflozin could offer a significant new therapeutic option for renal ischemia/reperfusion injury, even in nondiabetic patients. These findings expand the clinical utility of dapagliflozin beyond its current indications, addressing a major challenge with limited existing treatments.
Article 4: Cardiac resynchronisation therapy among adults with a systemic right ventricle: a multicentre experience.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41198182
Summary: This international retrospective study from 33 centers aimed to clarify the benefits of cardiac resynchronization therapy in adults with congenital heart disease and a systemic right ventricle. While cardiac resynchronization therapy is a key treatment for heart failure in acquired heart disease, its efficacy in patients with a systemic right ventricle, such as those with transposition of the great arteries or congenitally corrected transposition of the great arteries, remains undefined. This research establishes a crucial multicenter experience to assess whether this therapy improves outcomes for this specific and challenging patient population. The study addresses an important knowledge gap to optimize treatment strategies for adults living with complex congenital heart conditions.
Article 5: Higher Burden of Cerebral Small Vessel Disease Is Associated With Risk of Incident Stroke in Community-Dwelling Individuals.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41195792
Summary: This study investigated the association between a multimarker cerebral small vessel disease score and the risk of incident stroke in community-dwelling individuals from the Framingham Heart Study. Researchers found that a higher burden of cerebral small vessel disease, as identified by this novel multimarker score, is significantly associated with an increased risk of future stroke. This multimarker approach provides a more robust and comprehensive method for identifying individuals at risk than traditional methods or single cerebral small vessel disease markers. The findings offer a powerful new tool for improved stroke risk stratification and could lead to more targeted preventative strategies in the general population.
Transcript
Today’s date is November 07, 2025. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy. This Phase 3 trial investigated atacicept as a potential treatment for IgA nephropathy, a severe kidney disorder often leading to kidney failure or death in 50 percent of patients. Atacicept is a T.A.C.I.-Fc fusion protein designed to inhibit B-cell activating factor and a proliferation-inducing ligand, targeting the B-cell origin of the disease. This research establishes a crucial step in evaluating a specific immunomodulatory therapeutic approach for a condition affecting many patients with progressive kidney failure. The study explores a targeted strategy to improve outcomes in this prevalent primary glomerulopathy.
Article number two. Advancing Assessment Methods for Human Cardiac Grafts During Normothermic Machine Perfusion. This study focused on advancing assessment methods for human cardiac grafts during normothermic machine perfusion, addressing the critical challenge of donor heart scarcity in transplantation. Heart transplantation is the gold standard for end-stage heart failure, but only one-third of available donor hearts are currently utilized due to stringent selection criteria. By improving graft preservation and assessment through normothermic machine perfusion, this research aims to significantly increase the number of viable donor hearts. This advancement is crucial for expanding access to life-saving heart transplantation for millions affected by severe heart failure.
Article number three. Adenosine-mediated Neutrophil Regulation by Dapagliflozin Attenuates Renal Ischemia/Reperfusion Injury: Real-time Imaging and Metabolic Insights. This study investigated the renoprotective mechanisms of dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, in attenuating acute kidney injury resulting from ischemia/reperfusion injury in nondiabetic mice. Researchers found that dapagliflozin achieved its protective effects through adenosine-mediated neutrophil regulation, a pathway further elucidated by concurrent treatment with an adenosine A2A receptor antagonist. This research provides crucial metabolic insights and demonstrates that dapagliflozin could offer a significant new therapeutic option for renal ischemia/reperfusion injury, even in nondiabetic patients. These findings expand the clinical utility of dapagliflozin beyond its current indications, addressing a major challenge with limited existing treatments.
Article number four. Cardiac resynchronisation therapy among adults with a systemic right ventricle: a multicentre experience. This international retrospective study from 33 centers aimed to clarify the benefits of cardiac resynchronization therapy in adults with congenital heart disease and a systemic right ventricle. While cardiac resynchronization therapy is a key treatment for heart failure in acquired heart disease, its efficacy in patients with a systemic right ventricle, such as those with transposition of the great arteries or congenitally corrected transposition of the great arteries, remains undefined. This research establishes a crucial multicenter experience to assess whether this therapy improves outcomes for this specific and challenging patient population. The study addresses an important knowledge gap to optimize treatment strategies for adults living with complex congenital heart conditions.
Article number five. Higher Burden of Cerebral Small Vessel Disease Is Associated With Risk of Incident Stroke in Community-Dwelling Individuals. This study investigated the association between a multimarker cerebral small vessel disease score and the risk of incident stroke in community-dwelling individuals from the Framingham Heart Study. Researchers found that a higher burden of cerebral small vessel disease, as identified by this novel multimarker score, is significantly associated with an increased risk of future stroke. This multimarker approach provides a more robust and comprehensive method for identifying individuals at risk than traditional methods or single cerebral small vessel disease markers. The findings offer a powerful new tool for improved stroke risk stratification and could lead to more targeted preventative strategies in the general population.
Thank you for listening. Don’t forget to subscribe.
Keywords
neutrophils, incident stroke, multimarker score, risk stratification, Heart transplantation, glomerulopathy, cardiac grafts, IgA nephropathy, heart failure, Cerebral small vessel disease, systemic right ventricle, Cardiac resynchronization therapy, B-cell proliferation-inducing ligand, end-stage heart failure, sodium-glucose cotransporter 2 inhibitor, normothermic machine perfusion, adenosine signaling, acute kidney injury, transposition of the great arteries, atacicept, congenital heart disease, Dapagliflozin, Framingham Heart Study, B-cell activating factor, renal ischemia/reperfusion injury, donor heart assessment.
About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • FollowThe post Dapagliflozin Shields Kidneys from Acute Injury. 11/07/25 first appeared on Cardiology Today.
Article Links:
Article 1: A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy. (The New England journal of medicine)
Article 2: Advancing Assessment Methods for Human Cardiac Grafts During Normothermic Machine Perfusion. (Transplantation)
Article 3: Adenosine-mediated Neutrophil Regulation by Dapagliflozin Attenuates Renal Ischemia/Reperfusion Injury: Real-time Imaging and Metabolic Insights. (Transplantation)
Article 4: Cardiac resynchronisation therapy among adults with a systemic right ventricle: a multicentre experience. (Heart (British Cardiac Society))
Article 5: Higher Burden of Cerebral Small Vessel Disease Is Associated With Risk of Incident Stroke in Community-Dwelling Individuals. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/dapagliflozin-shields-kidneys-from-acute-injury-11-07-25/
Featured Articles
Article 1: A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41196369
Summary: This Phase 3 trial investigated atacicept as a potential treatment for IgA nephropathy, a severe kidney disorder often leading to kidney failure or death in 50 percent of patients. Atacicept is a T.A.C.I.-Fc fusion protein designed to inhibit B-cell activating factor and a proliferation-inducing ligand, targeting the B-cell origin of the disease. This research establishes a crucial step in evaluating a specific immunomodulatory therapeutic approach for a condition affecting many patients with progressive kidney failure. The study explores a targeted strategy to improve outcomes in this prevalent primary glomerulopathy.
Article 2: Advancing Assessment Methods for Human Cardiac Grafts During Normothermic Machine Perfusion.
Journal: Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41195985
Summary: This study focused on advancing assessment methods for human cardiac grafts during normothermic machine perfusion, addressing the critical challenge of donor heart scarcity in transplantation. Heart transplantation is the gold standard for end-stage heart failure, but only one-third of available donor hearts are currently utilized due to stringent selection criteria. By improving graft preservation and assessment through normothermic machine perfusion, this research aims to significantly increase the number of viable donor hearts. This advancement is crucial for expanding access to life-saving heart transplantation for millions affected by severe heart failure.
Article 3: Adenosine-mediated Neutrophil Regulation by Dapagliflozin Attenuates Renal Ischemia/Reperfusion Injury: Real-time Imaging and Metabolic Insights.
Journal: Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41195983
Summary: This study investigated the renoprotective mechanisms of dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, in attenuating acute kidney injury resulting from ischemia/reperfusion injury in nondiabetic mice. Researchers found that dapagliflozin achieved its protective effects through adenosine-mediated neutrophil regulation, a pathway further elucidated by concurrent treatment with an adenosine A2A receptor antagonist. This research provides crucial metabolic insights and demonstrates that dapagliflozin could offer a significant new therapeutic option for renal ischemia/reperfusion injury, even in nondiabetic patients. These findings expand the clinical utility of dapagliflozin beyond its current indications, addressing a major challenge with limited existing treatments.
Article 4: Cardiac resynchronisation therapy among adults with a systemic right ventricle: a multicentre experience.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41198182
Summary: This international retrospective study from 33 centers aimed to clarify the benefits of cardiac resynchronization therapy in adults with congenital heart disease and a systemic right ventricle. While cardiac resynchronization therapy is a key treatment for heart failure in acquired heart disease, its efficacy in patients with a systemic right ventricle, such as those with transposition of the great arteries or congenitally corrected transposition of the great arteries, remains undefined. This research establishes a crucial multicenter experience to assess whether this therapy improves outcomes for this specific and challenging patient population. The study addresses an important knowledge gap to optimize treatment strategies for adults living with complex congenital heart conditions.
Article 5: Higher Burden of Cerebral Small Vessel Disease Is Associated With Risk of Incident Stroke in Community-Dwelling Individuals.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41195792
Summary: This study investigated the association between a multimarker cerebral small vessel disease score and the risk of incident stroke in community-dwelling individuals from the Framingham Heart Study. Researchers found that a higher burden of cerebral small vessel disease, as identified by this novel multimarker score, is significantly associated with an increased risk of future stroke. This multimarker approach provides a more robust and comprehensive method for identifying individuals at risk than traditional methods or single cerebral small vessel disease markers. The findings offer a powerful new tool for improved stroke risk stratification and could lead to more targeted preventative strategies in the general population.
Transcript
Today’s date is November 07, 2025. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy. This Phase 3 trial investigated atacicept as a potential treatment for IgA nephropathy, a severe kidney disorder often leading to kidney failure or death in 50 percent of patients. Atacicept is a T.A.C.I.-Fc fusion protein designed to inhibit B-cell activating factor and a proliferation-inducing ligand, targeting the B-cell origin of the disease. This research establishes a crucial step in evaluating a specific immunomodulatory therapeutic approach for a condition affecting many patients with progressive kidney failure. The study explores a targeted strategy to improve outcomes in this prevalent primary glomerulopathy.
Article number two. Advancing Assessment Methods for Human Cardiac Grafts During Normothermic Machine Perfusion. This study focused on advancing assessment methods for human cardiac grafts during normothermic machine perfusion, addressing the critical challenge of donor heart scarcity in transplantation. Heart transplantation is the gold standard for end-stage heart failure, but only one-third of available donor hearts are currently utilized due to stringent selection criteria. By improving graft preservation and assessment through normothermic machine perfusion, this research aims to significantly increase the number of viable donor hearts. This advancement is crucial for expanding access to life-saving heart transplantation for millions affected by severe heart failure.
Article number three. Adenosine-mediated Neutrophil Regulation by Dapagliflozin Attenuates Renal Ischemia/Reperfusion Injury: Real-time Imaging and Metabolic Insights. This study investigated the renoprotective mechanisms of dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, in attenuating acute kidney injury resulting from ischemia/reperfusion injury in nondiabetic mice. Researchers found that dapagliflozin achieved its protective effects through adenosine-mediated neutrophil regulation, a pathway further elucidated by concurrent treatment with an adenosine A2A receptor antagonist. This research provides crucial metabolic insights and demonstrates that dapagliflozin could offer a significant new therapeutic option for renal ischemia/reperfusion injury, even in nondiabetic patients. These findings expand the clinical utility of dapagliflozin beyond its current indications, addressing a major challenge with limited existing treatments.
Article number four. Cardiac resynchronisation therapy among adults with a systemic right ventricle: a multicentre experience. This international retrospective study from 33 centers aimed to clarify the benefits of cardiac resynchronization therapy in adults with congenital heart disease and a systemic right ventricle. While cardiac resynchronization therapy is a key treatment for heart failure in acquired heart disease, its efficacy in patients with a systemic right ventricle, such as those with transposition of the great arteries or congenitally corrected transposition of the great arteries, remains undefined. This research establishes a crucial multicenter experience to assess whether this therapy improves outcomes for this specific and challenging patient population. The study addresses an important knowledge gap to optimize treatment strategies for adults living with complex congenital heart conditions.
Article number five. Higher Burden of Cerebral Small Vessel Disease Is Associated With Risk of Incident Stroke in Community-Dwelling Individuals. This study investigated the association between a multimarker cerebral small vessel disease score and the risk of incident stroke in community-dwelling individuals from the Framingham Heart Study. Researchers found that a higher burden of cerebral small vessel disease, as identified by this novel multimarker score, is significantly associated with an increased risk of future stroke. This multimarker approach provides a more robust and comprehensive method for identifying individuals at risk than traditional methods or single cerebral small vessel disease markers. The findings offer a powerful new tool for improved stroke risk stratification and could lead to more targeted preventative strategies in the general population.
Thank you for listening. Don’t forget to subscribe.
Keywords
neutrophils, incident stroke, multimarker score, risk stratification, Heart transplantation, glomerulopathy, cardiac grafts, IgA nephropathy, heart failure, Cerebral small vessel disease, systemic right ventricle, Cardiac resynchronization therapy, B-cell proliferation-inducing ligand, end-stage heart failure, sodium-glucose cotransporter 2 inhibitor, normothermic machine perfusion, adenosine signaling, acute kidney injury, transposition of the great arteries, atacicept, congenital heart disease, Dapagliflozin, Framingham Heart Study, B-cell activating factor, renal ischemia/reperfusion injury, donor heart assessment.
About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • FollowThe post Dapagliflozin Shields Kidneys from Acute Injury. 11/07/25 first appeared on Cardiology Today.
More episodes of the podcast Cardiology Today
CRISPR-Cas9 Gene Editing for Lipids 11/11/25
11/11/2025
In God we trust